Alumend is a privately held biotech firm developing innovative medical products based on a platform tissue bonding technology. Products target the tissue adhesive and sealant industry, dermatology, neurology and vascular surgery. This technology will also be leveraged for local drug delivery and bulking/reconstructive surgery applications.
Eleison’s mission is to acquire, develop, and commercialize clinical stage drug candidates for “orphan” oncology indications, providing new hope for patients with rare life-threatening diseases. The company has two programs in late-stage development, glufosfamide and ILC, and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and additional information about Eleison can be found at www.eleison-pharma.com.